The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
SOTYKTU (Bristol-Myers Squibb Australia Pty Ltd)
Product name
SOTYKTU
Date registered
Evaluation commenced
Decision date
Approval time
222 (255 working days)
Active ingredients
deucravacitinib
Registration type
NCE/NBE
Indication
SOTYKTU is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.